{"brief_title": "Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus", "brief_summary": "The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.", "condition": ["Diabetes Mellitus, Type 2"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Comparator: Sitagliptin", "Comparator: Placebo", "Comparator: Pioglitazone", "Metformin"], "description": ["Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24", "Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24", "Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8", "Metformin rescue for patients meeting\npre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"], "arm_group_label": ["Sitagliptin 100 mg", "Placebo", "Sitagliptin 100 mg", "Placebo", "Sitagliptin 100 mg", "Placebo"], "other_name": ["Januvia", "ACTOS"], "criteria": "Inclusion Criteria: - Patient has type 2 diabetes mellitus (T2DM) - Patient is 18 years of age (or older) - Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period Exclusion Criteria: - Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis - Patient required insulin within the prior 8 weeks - Patient is on a weight loss program and is not in the maintenance phase - Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks - Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate) - Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease - Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis) - Patient has any of the following disorders within the past 6 months: Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder. - Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months - Patient has severe peripheral vascular disease - Patient has congestive heart failure - Patient is HIV positive - Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) - Patient has a history of neoplastic disease - Patient has a history of alcohol or drug abuse within the past 3 years - Patient has viral hepatitis (hepatitis B or C)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Pioglitazone", "Metformin", "Sitagliptin Phosphate"], "id": "NCT00086502"}